- One of the leading companies in pharmaceuticals and diagnostics
- Develops drugs in oncology, immunology, ophtalmology, infection disease, and neurology domains
- Over CHF 235B market cap as of now
- CHF 9.5M net profit in 2017
Kepler Cheuvreux |
Hold |
276 EUR
|
10.12.2020 |
Jefferies & Company Inc. |
Buy |
332 EUR
|
10.12.2020 |
JP Morgan Chase & Co. |
Buy |
369 EUR
|
07.12.2020 |
UBS AG |
Buy |
341 EUR
|
10.11.2020 |
Buy
Based on the analytics from 31 of the world's largest investment banks over the past 3 months
Target price
273.19 EUR(4.83% Growth potential)
Based on the data from 31 of the leading investment banks
Receive ideas for profitable investments - faster than the market
We will be sending you a letter once a week with the most relevant information
Congratulations!
Now you will always be aware of which stocks are more profitable to invest in